BREXPIPRAZOLE (Rexulti ®)

Clinical Indication

Antipsychotics

Comments

LPT prescribing group have reviewed and found no significant advantages over existing formulary products

Date of classification

February 2019

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety